The ongoing HIVEC HEAT trial aims to generate clinical data to evidence the efficacy of hyperthermic intravesical 80mg mitomycin C chemotherapy for patients with BCG-unresponsive, high risk NMIBC
May 27, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
The ongoing HIVEC HEAT trial aims to generate clinical data to evidence the efficacy of hyperthermic intravesical 80mg mitomycin C chemotherapy for patients with BCG-unresponsive, high risk NMIBC